Cannabis and Driving in Australia: How THC and CBD Affect Your Ability to Drive

Last updated: January 2026 | Educational guide — not medical or legal advice. Consult your prescribing clinician and a qualified legal professional for guidance specific to your situation.

As medical cannabis use grows across Australia — with the Therapeutic Goods Administration (TGA) recording over 900,000 approvals by late 2024 — understanding how cannabis affects your ability to drive safely has never been more important. This guide draws on peer-reviewed research, including landmark work from the University of Sydney's Lambert Initiative for Cannabinoid Therapeutics, to explain what the science currently says about THC, CBD, and driving impairment, and what it means for Australian patients and the law.

THC and Driving: What the Evidence Shows

Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive compound in cannabis and the component most associated with impaired driving performance. Research consistently shows that THC affects several cognitive and motor functions that are critical for safe driving.

Documented effects of THC on driving-relevant functions

• Divided attention: THC impairs the ability to process multiple streams of information simultaneously — a core demand of driving in traffic.
• Reaction time: Studies show slowed reaction times at doses producing blood THC concentrations above approximately 2–5 ng/mL, though individual sensitivity varies considerably.
• Lane tracking and vehicle control: Increased lateral lane weaving has been recorded in controlled driving simulator studies and on-road trials.
• Speed regulation: THC-impaired drivers often drive more slowly and increase following distance — a partial compensatory behaviour — but this does not reliably offset impairment in unexpected hazard scenarios.
• Short-term memory and decision-making: Working memory deficits can affect route planning and response to complex traffic situations.

A 2022 meta-analysis published in Neuroscience and Biobehavioral Reviews found that acute THC intoxication approximately doubles the relative risk of a motor vehicle crash compared to unimpaired driving. Risk increases further when THC is combined with alcohol, even at blood alcohol concentrations below the legal limit of 0.05.

How long is driving impairment likely to last after THC use?

The duration of THC-related impairment depends on route of administration, dose, product potency, and individual tolerance. As a general guide based on current research:

These figures represent conservative estimates. Residual impairment beyond peak blood THC levels is possible, and individual variation is significant. Heavy or long-term users may experience different impairment profiles. No reliable personal test exists to determine when you are safe to drive — only time eliminates THC impairment.

CBD and Driving: A Meaningfully Different Picture

Cannabidiol (CBD) is a non-intoxicating cannabinoid and is the active ingredient in several TGA-approved and Schedule 4 pharmaceutical products prescribed in Australia. Unlike THC, CBD does not produce psychoactive effects and does not bind strongly to CB1 receptors in the brain.

Key findings from the Arkell et al. research

Researchers at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney — including Dr Tom Arkell — conducted some of the most rigorous real-world driving studies on cannabis and cannabinoids conducted anywhere in the world. Their 2021 study, published in the Journal of Psychopharmacology, found:

• Vaporised CBD at a 400 mg dose did not significantly impair driving performance on a standardised on-road driving test compared to placebo.
• THC at 13.75 mg produced clear driving impairment, particularly in the first four hours after vaporisation.
• A balanced THC:CBD combination showed impairment similar to THC alone in the first four hours, suggesting CBD does not meaningfully reverse THC-induced driving impairment at these doses.
• By the four-hour mark, driving performance in the THC and THC:CBD groups was largely comparable to placebo, though individual variation was noted.

These findings provide important reassurance for patients using CBD-dominant or CBD-isolate pharmaceutical products. However, this does not mean CBD products carry zero driving risk — patients should always review their specific product with their prescribing clinician, as many real-world medical cannabis products contain some level of THC alongside CBD.

The Australian Legal Framework: What Every Driver Must Know

Australian road law creates a critical distinction that many drivers — including medical cannabis patients — do not fully appreciate: the law does not test for impairment; it tests for the presence of THC.

Drug driving laws across Australian states and territories

All Australian states and territories operate roadside drug testing (RDT) programs that detect the presence of THC in oral fluid (saliva). Testing is not impairment-based — a positive result for THC is an offence regardless of whether you feel impaired or whether your prescription is valid.

As of January 2026, no Australian state or territory provides a legal exemption permitting a medical cannabis patient to drive with detectable THC. This remains an active area of policy debate, but patients must operate within the current legal reality. Penalties for a positive RDT vary by jurisdiction and prior history but can include fines, licence suspension, and in some cases criminal charges.

How long does THC remain detectable in oral fluid?

Oral fluid testing detects recent use, but detectability windows vary. Research suggests THC can be detected in saliva for between 4 and 12 hours after use in most people, though in some individuals — particularly regular users — detection can extend beyond 24 hours. Blood THC tests in confirmatory laboratory analysis may detect THC for longer periods still. CBD is not targeted by Australian roadside drug tests and does not produce a positive THC result.

Practical Harm-Reduction Advice for Medical Cannabis Patients

If you are a medical cannabis patient in Australia, the following evidence-informed steps can help you manage both your safety and your legal obligations. This information is educational — always discuss driving and your specific treatment plan with your prescribing clinician.

• Talk to your prescriber before driving: Your doctor can help you understand your specific product's THC content, your dosing schedule, and a safe waiting period before driving. Do not assume a product is safe to drive with because it is prescribed.
• Plan your dosing schedule around driving: If you need to drive the following morning, discuss evening dosing options with your clinician. Some patients are able to schedule doses to allow adequate time before driving.
• Know your product: Many Australian medical cannabis products are full-spectrum or broad-spectrum and contain THC even if labelled as CBD products. Check your Certificate of Analysis (CoA) and confirm THC levels with your pharmacy or prescriber.
• Apply conservative time windows: Given individual variation in metabolism and the zero-tolerance legal standard, always apply the more conservative end of any estimated impairment window.
• Never combine THC with alcohol before driving: Even sub-limit amounts of alcohol significantly potentiate THC impairment. This combination is particularly dangerous and can amplify both impairment and legal risk.
• Consider alternative transport: On days when you have taken a THC-containing product and are uncertain about detection or impairment, use public transport, rideshare, or arrange for someone else to drive.
• Keep your prescription documentation: While a valid prescription does not exempt you from a positive RDT offence, it may be relevant to associated criminal proceedings or character considerations. Maintain up-to-date documentation from your prescriber.

The Policy Conversation in Australia

Medical cannabis advocates, researchers, and patient organisations continue to call for reform of Australia's drug driving laws to account for the difference between detectable THC and actual impairment. Organisations including the Lambert Initiative and the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE) have contributed to this discourse. The argument for reform centres on the fact that existing laws may unfairly penalise patients who use prescribed medication responsibly and are not functionally impaired at the time of driving.

Until legislative change occurs, however, the legal position is clear and applies equally to all drivers. Patients should monitor developments in their state or territory and engage with their treating clinician regularly about how evolving evidence and policy may affect their treatment and lifestyle.

Summary

• THC impairs driving-relevant functions and meaningfully increases crash risk. Impairment is dose, route, and individual dependent.
• CBD alone, at therapeutic doses, does not appear to significantly impair driving performance based on current evidence.
• CBD does not offset THC-related impairment in combination products.
• Australian drug driving laws are presence-based, not impairment-based. No state or territory currently exempts medical cannabis patients from positive THC detection offences.
• Always discuss driving with your prescribing clinician. Do not make assumptions about safety based on how you feel.